Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Sabina Signoretti, M.D.

Co-Author

This page shows the publications co-authored by Sabina Signoretti and Toni Choueiri.
Connection Strength

12.118
  1. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2178-2184.
    View in: PubMed
    Score: 0.605
  2. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013 Sep 15; 19(18):5218-26.
    View in: PubMed
    Score: 0.560
  3. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
    View in: PubMed
    Score: 0.557
  4. Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013 Feb; 14(2):105-7.
    View in: PubMed
    Score: 0.540
  5. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol. 2013 Nov; 31(8):1788-93.
    View in: PubMed
    Score: 0.533
  6. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012 Nov; 62(5):917-22.
    View in: PubMed
    Score: 0.518
  7. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8.
    View in: PubMed
    Score: 0.442
  8. Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. J Clin Oncol. 2009 May 20; 27(15_suppl):e16067.
    View in: PubMed
    Score: 0.419
  9. Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):16042.
    View in: PubMed
    Score: 0.391
  10. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. J Natl Cancer Inst. 2021 03 01; 113(3):234-243.
    View in: PubMed
    Score: 0.237
  11. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.236
  12. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
    View in: PubMed
    Score: 0.233
  13. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 08 01; 6(8):1247-1255.
    View in: PubMed
    Score: 0.228
  14. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.225
  15. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunol Res. 2020 08; 8(8):1075-1084.
    View in: PubMed
    Score: 0.223
  16. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. J Clin Oncol. 2020 01 01; 38(1):63-70.
    View in: PubMed
    Score: 0.217
  17. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 10 15; 25(20):6080-6088.
    View in: PubMed
    Score: 0.212
  18. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.205
  19. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2018 07; 6(7):758-765.
    View in: PubMed
    Score: 0.195
  20. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. Br J Cancer. 2018 05; 118(9):1238-1242.
    View in: PubMed
    Score: 0.194
  21. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436.
    View in: PubMed
    Score: 0.188
  22. In Reply. Oncologist. 2017 12; 22(12):1561.
    View in: PubMed
    Score: 0.186
  23. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol. 2017 10; 72(4):557-564.
    View in: PubMed
    Score: 0.181
  24. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292.
    View in: PubMed
    Score: 0.179
  25. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503. Urol Oncol. 2017 03; 35(3):117-118.
    View in: PubMed
    Score: 0.179
  26. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Oct 20; 34(30):3655-3663.
    View in: PubMed
    Score: 0.175
  27. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
    View in: PubMed
    Score: 0.172
  28. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
    View in: PubMed
    Score: 0.170
  29. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
    View in: PubMed
    Score: 0.169
  30. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6.
    View in: PubMed
    Score: 0.167
  31. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
    View in: PubMed
    Score: 0.167
  32. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 01; 121(19):3435-43.
    View in: PubMed
    Score: 0.159
  33. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64.
    View in: PubMed
    Score: 0.159
  34. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
    View in: PubMed
    Score: 0.156
  35. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817.
    View in: PubMed
    Score: 0.155
  36. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015 Mar 01; 21(5):1071-7.
    View in: PubMed
    Score: 0.154
  37. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.148
  38. MET as a target in papillary renal cell carcinoma. Clin Cancer Res. 2014 Jul 01; 20(13):3361-3.
    View in: PubMed
    Score: 0.148
  39. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.134
  40. Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET). J Clin Oncol. 2012 Feb 10; 30(5_suppl):352.
    View in: PubMed
    Score: 0.127
  41. Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4506.
    View in: PubMed
    Score: 0.120
  42. Treatment selection for patients with metastatic renal cell carcinoma. Cancer. 2009 May 15; 115(10 Suppl):2327-33.
    View in: PubMed
    Score: 0.105
  43. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Sep 15; 21(1):1023.
    View in: PubMed
    Score: 0.062
  44. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 07; 21(1):904.
    View in: PubMed
    Score: 0.061
  45. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):649-661.e5.
    View in: PubMed
    Score: 0.059
  46. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.059
  47. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med. 2021 01 20; 13(577).
    View in: PubMed
    Score: 0.059
  48. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.058
  49. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2021 01 01; 27(1):78-86.
    View in: PubMed
    Score: 0.057
  50. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
    View in: PubMed
    Score: 0.055
  51. Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Mol Cancer Ther. 2020 02; 19(2):690-696.
    View in: PubMed
    Score: 0.054
  52. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun. 2019 09 25; 10(1):4346.
    View in: PubMed
    Score: 0.054
  53. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.052
  54. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019 04 08; 10(1):1617.
    View in: PubMed
    Score: 0.052
  55. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018 09; 14(9):e1007679.
    View in: PubMed
    Score: 0.050
  56. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.050
  57. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12):3698.
    View in: PubMed
    Score: 0.049
  58. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):341-348.
    View in: PubMed
    Score: 0.049
  59. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 04 03; 23(1):313-326.e5.
    View in: PubMed
    Score: 0.048
  60. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 Feb 16; 359(6377):801-806.
    View in: PubMed
    Score: 0.048
  61. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. Kidney Cancer. 2017 Jul 26; 1(1):31-40.
    View in: PubMed
    Score: 0.046
  62. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017 10; 198(4):817-823.
    View in: PubMed
    Score: 0.045
  63. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 06 10; 6:27702.
    View in: PubMed
    Score: 0.043
  64. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016 07; 48(7):725-32.
    View in: PubMed
    Score: 0.043
  65. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. 2016 May 24; 7(21):29901-15.
    View in: PubMed
    Score: 0.043
  66. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
    View in: PubMed
    Score: 0.041
  67. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  68. Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol. 2014 Dec 22; 14:138.
    View in: PubMed
    Score: 0.039
  69. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res. 2015 Jan; 13(1):130-7.
    View in: PubMed
    Score: 0.038
  70. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53.
    View in: PubMed
    Score: 0.038
  71. Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014; 9(8):e103325.
    View in: PubMed
    Score: 0.038
  72. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
    View in: PubMed
    Score: 0.037
  73. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
    View in: PubMed
    Score: 0.036
  74. Assessment of a cell-line-derived HIF1a gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib. J Clin Oncol. 2012 Feb 10; 30(5_suppl):408.
    View in: PubMed
    Score: 0.032
  75. Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
    View in: PubMed
    Score: 0.030
  76. Identification of ALK gene alterations in urothelial carcinoma (UC). J Clin Oncol. 2011 May 20; 29(15_suppl):4568.
    View in: PubMed
    Score: 0.030
  77. RET protein expression in papillary renal cell carcinoma. Urol Oncol. 2012 Nov-Dec; 30(6):900-5.
    View in: PubMed
    Score: 0.030
  78. Risk of bilateral renal cell cancer. J Clin Oncol. 2009 Aug 10; 27(23):3737-41.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.